Decoy Therapeutics partners with hVIVO to advance D-MAV antivirals into Phase 1, Phase 2a studies

Decoy

Decoy

DCOY

0.00
  • Decoy Therapeutics signed a strategic development initiative with clinical partner hVIVO to move its lead D-MAV antiviral into Phase 1 and Phase 2a studies.
  • hVIVO will support trial planning, regulatory strategy, translational modeling, and preparation of European and UK clinical trial submissions, including EMA and MHRA interactions.
  • The work is intended to create a reusable development template across Decoy’s D-MAV portfolio, subject to regulatory feedback.
  • Decoy plans to pursue early proof-of-concept studies with hVIVO, while also targeting US registration with the FDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.